Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C.
Suraweera D, Weeratunga AN, Saab S.
Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s90537 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för grazoprevir. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
19 träffarElbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.
Bell AM, Wagner JL, Barber KE, Stover KR.
Int J Hepatol · research-article; review; journal article · DOI 10.1155/2016/3852126Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, Howe AY, Wahl J, Bhanja S, Hwang P, Zhao Y, Robertson MN.
J Viral Hepat · randomized controlled trial; journal article · DOI 10.1111/jvh.12552Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C.
Carrion AF, Martin P.
Expert Opin Drug Saf · review; journal article · DOI 10.1080/14740338.2016.1179278The Discovery of Quinoxaline-Based Metathesis Catalysts from Synthesis of Grazoprevir (MK-5172).
Williams MJ, Kong J, Chung CK, Brunskill A, Campeau LC, McLaughlin M.
Org Lett · journal article · DOI 10.1021/acs.orglett.6b00070The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.
Antimicrob Agents Chemother · research-article; journal article · DOI 10.1128/aac.00051-16Elbasvir/Grazoprevir: First Global Approval.
Keating GM.
Drugs · review; journal article · DOI 10.1007/s40265-016-0558-3Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
Alric L, Bonnet D.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2016.1161028Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.
Landaverde C, Wells J, Hamner R, Goldstein JL.
Expert Rev Gastroenterol Hepatol · review; journal article · DOI 10.1586/17474124.2016.1147346Elbasvir/grazoprevir (Zepatier) for hepatitis C.
Författaruppgift saknas
Med Lett Drugs Ther · review; journal articleStructural and Thermodynamic Effects of Macrocyclization in HCV NS3/4A Inhibitor MK-5172.
Soumana DI, Kurt Yilmaz N, Prachanronarong KL, Aydin C, Ali A, Schiffer CA.
ACS Chem Biol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acschembio.5b00647Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
Sulejmani N, Jafri SM, Gordon SC.
Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2016.1148685Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.
Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N.
J Viral Hepat · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/jvh.12464Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M.
Lancet HIV · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/s2352-3018(15)00114-9Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.
Lancet · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(14)61793-1Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.
Lancet · clinical trial, phase ii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(14)61795-5Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.
Tong X, Kwong AD.
Clin Infect Dis · comment; editorial · DOI 10.1093/cid/ciu700The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AY, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N.
Gastroenterology · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1053/j.gastro.2014.04.006MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.
Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.2014.902049